Expression of micrornas in molecular genetic breast cancer subtypes

Kolesnikov, N. N.; Veryaskina, Yu. A.; Титов, С. Е.; Родионов, В В; Генинг, Т. П.; Абакумова, Т. В.; Kometova, Kometova V.V.; Torosyan, M.Kh.; Жимулев, И. Ф.

doi:10.1016/j.ctarc.2016.08.006

Cited by 10 publications

(6 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ER and PR can regulate gene transcription either by directly binding to DNA response elements directly or indirectly via other transcription factors such as induction and coregulator recruiting and noncoding RNA regulation . In addition, ER and PR could interact with several proteins and regulate cell signaling pathways through nongenomic mechanisms. , The molecular and cellular mechanism underlying the effect of 4 H -benzo[ d ][1,3]oxazines is under study in our research group.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Gold(I)-Catalyzed Synthesis of 4H-Benzo[d][1,3]oxazines and Biological Evaluation of Activity in Breast Cancer Cells

et al. 2022

View full text Add to dashboard Cite

The first gold(I)-catalyzed cycloisomerization procedure applied to the synthesis of substituted 4 H -benzo[ d ][1,3]oxazines has been developed starting from N -(2-alkynyl)aryl benzamides. The chemoselective oxygen cyclization via the 6- exo -dig pathway yielded the observed heterocycles in modest to good chemical yields under very mild reaction conditions. The obtained oxazines were assayed on the breast cancer (BC)-derived cell lines MCF-7 and HCC1954 with differential biological activity. The newly synthesized 4 H -benzo[ d ][1,3]oxazine compounds showed several degrees of cell proliferation inhibition with a remarkable effect for those compounds having a substituted aryl at C-2 of the molecules. The 4 H -benzo[ d ][1,3]oxazines showed an IC 50 ranking from 3.1 to 95 μM in MCF-7 and HCC1954 cells. These compounds represent potential drug candidates for BC treatment. However, additional assays are needed to elucidate their complete effect over the cellular and molecular hallmarks of cancer.

show abstract

Section: Resultsmentioning

confidence: 99%

“…47 In addition, ER and PR could interact with several proteins and regulate cell signaling pathways through nongenomic mechanisms. 48,49 The molecular and cellular mechanism underlying the effect of 4Hbenzo[d] [1,3]oxazines is under study in our research group.…”

Section: ■ Results and Discussionmentioning

confidence: 99%

Gold(I)-Catalyzed Synthesis of 4H-Benzo[d][1,3]oxazines and Biological Evaluation of Activity in Breast Cancer Cells

et al. 2022

View full text Add to dashboard Cite

show abstract

“…It's responsible for 33% of HER2 positive cases and 50% of triple negative ones. Although the blood-brain barrier (BBB) protects the central nervous system (CNS) from infectious and metabolic stresses, the prevalence of CNS (central nervous system) metastases is high, most likely because of the poor prognosis and high death rate associated with these tumors [48]. Tight junctions of specialized vascular endothelium provide the foundation of the BBB, which is further strengthened by astrocytes and pericytes.…”

Section: Brainmentioning

confidence: 99%

Nano-therapeutic targeting of the tumor microenvironment in metastatic breast cancer: Current state and future prospects

Hansen,

Aaberg,

Landvik

2023

Preprint

View full text Add to dashboard Cite

The tumour-microenvironment (TME) is a complex network of cells and molecules that has a major impact on the development, dissemination, and progression of cancer metastasis. It is made up of stromal cells, tumour cells, cancerassociated blood and lymphatic vessels, pericytes, cancer-associated fibroblasts, cancer-stem cells, and extracellular matrix (ECM). Metastatic breast cancer is one of the most difficult to treat forms of the disease. This calls for a comprehensive comprehension of the metastatic TME and the development of novel nano-drug delivery systems that leverage specific cellular components. Nanoparticles (NPs) that respond to external stimuli provide improved control over where and when cells are targeted. Nano-therapies need to be safe, effective and scalable in manufacturing for translation to clinics. Emerging nano-strategies, in contrast to traditional medicines that promote systemic ablation, selectively control the diverse TME cell populations by, for example, focusing on pericytes and endothelial cells to normalize vascular function. We also describe the gaps in the present nanotherapeutics approaches and highlight innovative views on the design of pre-clinical and clinical trials to alter breast cancer's ability to spread.

show abstract

“…A search of PubMed (accessed February 24, 2019; search term ‘breast AND cancer AND triple negative AND miRNA) found 548 reports on this topic. The most notable of these are included in Tables III ( 23 , 35 – 62 ) and IV ( 36 , 37 , 46 , 63 – 65 ), where there is a brief description of some of the most representative meta-analyses.…”

Section: Mirnas As Biomarkers In Bcmentioning

confidence: 99%

Circulating microRNAs and their role in the immune response in triple‑negative breast cancer (Review)

2020

View full text Add to dashboard Cite

Breast cancer (BC) is the most common type of cancer in women worldwide, and despite advances in treatments, its incidence and mortality are increasing. Therefore, it is necessary to develop new, non-invasive tests that provide more accurate diagnosis and prognosis in a timely manner. A promising approach is measuring the presence of biomarkers to detect tumors at various stages and determine their specific characteristics, thus allowing for more personalized treatment. MicroRNAs (miRNAs) serve a role in gene expression, primarily by interacting with messenger RNAs, and may be potential biomarkers for detecting cancer. They are detectable in tissues and blood, including plasma and/or serum, are stable and often tumor specific. Also, different miRNAs are associated with specific BC molecular subtypes. Triple-negative BC (TNBC) is a type of BC in which the primary targets for hormonal therapy are absent. It is an aggressive phenotype, which frequently metastasizes and is associated with an unfavorable prognosis. The present review focuses on circulating miRNAs in patients with TNBC, with an emphasis on their interaction with the immune response checkpoint genes PD-1, PD-L1 and CTLA4. Modulation and response of the immune system are of interest in cancer treatment due to the success of immunotherapy in the treatment of various neoplasms. Based on the findings of this literature review and the in silico analysis performed as part of this review, it is concluded that circulating hsa-miR-195 and hsa-miR-155 in TNBC interact with checkpoint genes involved in the immune response. Further analysis of the expression of these circulating miRNAs and their association with prognosis in patients with TNBC treated with immunotherapy should be assessed to evaluate their possible use as non-invasive predictive biomarkers. In addition, functional studies to analyze biologically relevant targets in the development and prognosis of TNBC, which could be therapeutic targets, are also recommended. Contents 1. Introduction 2. miRNAs as biomarkers in BC 3. Circulating miRNAs in BC 4. Checkpoints and miRNAs in TNBC 5. Conclusions

show abstract

Expression of micrornas in molecular genetic breast cancer subtypes

Cited by 10 publications

References 24 publications

Gold(I)-Catalyzed Synthesis of 4H-Benzo[d][1,3]oxazines and Biological Evaluation of Activity in Breast Cancer Cells

Gold(I)-Catalyzed Synthesis of 4H-Benzo[d][1,3]oxazines and Biological Evaluation of Activity in Breast Cancer Cells

Nano-therapeutic targeting of the tumor microenvironment in metastatic breast cancer: Current state and future prospects

Circulating microRNAs and their role in the immune response in triple‑negative breast cancer (Review)

Contact Info

Product

Resources

About